3. REVENUE FROM CONTRACTS WITH CUSTOMERS

 

During the years ended December 31, 2025, 2024 and 2023, the Company recorded product sales, net, as follows:

 

 

Year Ended December 31,

 

(In thousands)

2025

 

 

2024

 

 

2023

 

VIVITROL

$

467,912

 

 

$

457,315

 

 

$

400,419

 

ARISTADA and ARISTADA INITIO

 

370,044

 

 

 

346,187

 

 

 

327,690

 

LYBALVI

 

346,687

 

 

 

280,032

 

 

 

191,889

 

Total product sales, net

$

1,184,643

 

 

$

1,083,534

 

 

$

919,998

 

 

During the years ended December 31, 2025, 2024 and 2023, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

 

 

 

Year Ended December 31, 2025

 

(In thousands)

 

Manufacturing
Revenue

 

 

Royalty
Revenue

 

 

Total

 

Long-acting INVEGA products(1)

 

$

 

 

$

109,572

 

 

$

109,572

 

VUMERITY

 

 

16,539

 

 

 

113,929

 

 

 

130,468

 

RISPERDAL CONSTA

 

 

19,569

 

 

 

55

 

 

 

19,624

 

Other

 

 

9,887

 

 

 

21,705

 

 

 

31,592

 

 

$

45,995

 

 

$

245,261

 

 

$

291,256

 

 

 

 

Year Ended December 31, 2024

 

(In thousands)

 

Manufacturing
Revenue

 

 

Royalty
Revenue

 

 

Total

 

Long-acting INVEGA products(1)

 

$

 

 

$

236,386

 

 

$

236,386

 

VUMERITY

 

 

39,292

 

 

 

94,755

 

 

 

134,047

 

RISPERDAL CONSTA

 

 

23,172

 

 

 

272

 

 

 

23,444

 

Other

 

 

56,962

 

 

 

23,256

 

 

 

80,218

 

 

$

119,426

 

 

$

354,669

 

 

$

474,095

 

 

 

 

Year Ended December 31, 2023

 

(In thousands)

 

Manufacturing Revenue

 

 

Royalty Revenue

 

 

Total

 

Long-acting INVEGA products(1)

 

$

 

 

$

486,101

 

 

$

486,101

 

VUMERITY

 

 

42,886

 

 

 

86,440

 

 

 

129,326

 

RISPERDAL CONSTA

 

 

36,123

 

 

 

1,153

 

 

 

37,276

 

Other

 

 

63,489

 

 

 

27,196

 

 

 

90,685

 

 

$

142,498

 

 

$

600,890

 

 

$

743,388

 

 

(1)
“long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

In November 2021, the Company received notice of partial termination of an exclusive license agreement with Janssen. Under this license agreement, the Company provided Janssen with rights to, and know-how, training and technical assistance in respect of, the Company’s small particle pharmaceutical compound technology, known as NANOCRYSTAL technology, which was used to develop the long-acting INVEGA products. When the partial termination became effective in February 2022, Janssen ceased paying royalties related to sales of INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA. Accordingly, the Company ceased recognizing royalty revenue related to sales of these products in February 2022. In April 2022, the Company commenced binding arbitration proceedings related to, among other things, Janssen’s partial termination of this license agreement and Janssen’s royalty and other obligations under the agreement. In May 2023, the arbitral tribunal (the “Tribunal”) in the arbitration proceedings issued a final award (the “Final Award”) which concluded the arbitration proceedings. The Final Award provided, among other things, that the Company was due back royalties of $195.4 million, inclusive of $8.1 million in late-payment interest related to 2022 U.S. net sales of the long-acting INVEGA products, which amount the Company received from Janssen in the second quarter of 2023, and is entitled to 2023 and future royalty revenues from Janssen related to net sales of INVEGA SUSTENNA through August 20, 2024, INVEGA TRINZA through the second quarter of 2030 (but no later than May 2030 when the license agreement expires) and INVEGA HAFYERA through May 2030 (when the license agreement expires).

Following issuance of the Final Award, the Company recognized royalty revenues related to the back royalties noted above and resumed recognizing royalty revenue related to ongoing U.S. sales of the long-acting INVEGA products. During 2023, the Company recorded $486.1 million in royalty revenue from sales of the long-acting INVEGA products, including $195.4 million in back royalties and associated interest related to net sales of the long-acting INVEGA in the U.S. in 2022, and approximately $290.7 million related to resumed recognition of royalty revenue related to worldwide net sales of the long-acting INVEGA products.

Historical Timeline

Fiscal YearFiled
2025Feb 25, 2026Showing above
2024Feb 12, 2025
2023Feb 21, 2024
2022Feb 16, 2023
2021Feb 16, 2022
2020Feb 11, 2021
2019Feb 13, 2020
2018Feb 15, 2019

About Revenue Disclosures

Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.

Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.